The Australian government is warning doctors and patients that certain pieces used in hip replacements—including those used by surgeons in the United States—may stop working properly, potentially causing loss of mobility, pain, broken bones, metal poisoning, and need for additional surgery.
We previously reported that the Attorneys General for Washington and California filed suit against Johnson & Johnson, one of the world’s largest manufacturers of transvaginal mesh, over concerns that the company intentionally misled the public about the dangers of the permanent implants.
Most people reasonably believe that when a product is cleared by the Food and Drug Administration, there has at least been some kind of independent review of the product. Many probably assume that the review is ongoing, so long as the product remains in use. Unfortunately, this is rarely true. The FDA relies on pharmaceutical companies to be truthful about their own products. As expected, profits and human error can get in the way.
More Than Fifteen Million Americans Use Heartburn Drugs Each Year – Why Weren’t They Warned About Possible Kidney Injury?
You’ve seen the commercials: one pill a day—zero heartburn! Maybe you even read the previous sentence in the voice of Larry the Cable Guy. But what you haven’t seen in those commercials are the risks. Because over-the-counter medications are regulated differently than prescription medications, the “OTC” versions of popular heartburn medicines are not required to disclose in commercials the potential health risks associated with the drugs.
Boston Scientific Corporation announced this summer that it is once again adding new warnings to the labels for its surgical mesh devices. According to the Minneapolis Star Tribune, the products will now warn of “ongoing pain.” The labels will also finally disclose that mesh devices are permanent implants, that removal may be complicated or impossible, and that treatment for post-implant complications may require surgical removal of the device.
Bayer Healthcare previously “raised its forecast for Xarelto’s 2015 sales growth to 30 percent from 20 percent,” according to a report by Reuters. Xarelto is the heavily-advertised anticoagulant drug produced by Bayer and Johnson & Johnson’s pharmaceutical wing.
Sean Keith is a native of Rogers, Arkansas and a second generation attorney. Sean completed his undergraduate degree at Westminster College in Fulton, Missouri, and received his law degree from the University of Arkansas at Fayetteville. Read More
Mason Boling primarily represents plaintiffs in personal injury claims against pharmaceutical and medical device companies. He also writes appeals for both civil and criminal cases and assists in other forms of civil litigation and criminal defense. Read More
Poplar Plaza Building
224 South 2nd St.
Rogers, AR 72756
Ball Plaza Building
112 W. Center St. #555
Fayetteville, AR 72701